Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aplindore SCHEMBL3192098 | 0.87 | DRD2 (0.68) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| Aplindore SCHEMBL119499 | 0.87 | DRD2 (0.68) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| Aplindore SCHEMBL29359212 | 0.87 | DRD2 (0.68) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| SCHEMBL5957109 | 0.82 | DRD2 (0.58) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| Aplindore SCHEMBL5954695 | 0.81 | DRD2 (0.60) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| Aplindore SCHEMBL1231153 | 0.81 | DRD2 (0.60) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| Aplindore SCHEMBL29470967 | 0.81 | DRD2 (0.60) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| SCHEMBL5957062 | 0.77 | DRD2 (0.52) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| SCHEMBL5957081 | 0.77 | DRD2 (0.55) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| SCHEMBL5957139 | 0.77 | DRD2 (0.55) | DRD2DRD4DRD3ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662979-B2 | cyanation; dopamine autoreceptor agonists and partial agonists at postsynaptic dopamine D2 receptor; for treating dopaminergic disorders such as schizophrenia, schizoaffective disorder, Parkinson's disease, Tourette's syndrome, hyperprolactinemia, and drug addiction | WYETH (US) | 2010-02-16 | — | — | US | disclosed |
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | HTR5A, OPRL1, SLC6A3 | DRD2 7/4885DRD4 22/4885DRD3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.